Kathryn J. Ruddy, MD, MPH, of the Mayo Clinic, summarizes a special spotlight session that included discussion of interventions to improve quality of life and the importance of lifestyle in the prevention of cancer and cancer recurrence.
Shanu Modi, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings from a large phase I study on trastuzumab deruxtecan in patients with low HER2-expressing breast cancer (Abstract P6-17-02).
Dejan Juric, MD, of Massachusetts General Hospital, discusses phase III study findings on liquid biopsy–based assessment of PIK3CA mutational status and the combination of the selective PI3K-alpha inhibitor alpelisib plus fulvestrant in the treatment of advanced breast cancer (Abstract GS3-08).
Judy E. Garber, MD, of the Dana-Farber Cancer Institute, summarizes a special session she moderated, which included discussion of polygenic risk scores, genetic testing in diverse populations, and what to do when presented with moderate-penetrance mutations.
François-Clément Bidard, MD, PhD, of the Institut Curie and the University of Versailles, discusses phase III study findings on the clinical utility of circulating tumor cell count as a tool to choose between first-line hormone therapy and chemotherapy for estrogen receptor–positive, HER2-negative metastatic breast cancer (Abstract GS3-07).
Reshma Jagsi, MD, DPhil, of the University of Michigan, and Rachel A. Freedman, MD, MPH, of Dana-Farber Cancer Institute, discuss the twin challenges of overtreating people with cancer and the missed opportunities and dangers of undertreatment.
